Invivyd Management
Management Kriterienprüfungen 3/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Marc Elia
Geschäftsführender
US$126.0k
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | n/a |
| Amtszeit als Geschäftsführer | less than a year |
| Eigentum des Geschäftsführers | n/a |
| Durchschnittliche Amtszeit des Managements | 2.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 2.3yrs |
Jüngste Management Updates
Recent updates
Analyseartikel • Jul 10
Here's Why We're Not Too Worried About Invivyd's (NASDAQ:IVVD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Narrative-Update • Jun 23
IVVD: Phase 3 Prophylaxis Readouts And BLA Prospect Will Drive Upside
Analysts have kept their $10.00 price target on Invivyd steady, citing the recent post earnings selloff as overdone, given that the Q1 revenue shortfall and higher $30.7 million research and development spend are viewed as timing related and tied to pivotal investments ahead of the key VYD2311 data readout and potential biologics license application. What’s in the News for Invivyd Invivyd completed enrollment in the Phase 3 DECLARATION trial of VYD2311, assessing a single intramuscular dose and monthly dosing versus placebo for prevention of symptomatic COVID-19 over 90 days, with approximately 2,400 participants enrolled.Narrative-Update • Jun 05
IVVD: Phase 3 Prophylaxis Progress And BLA Pathway Will Drive Upside
Narrative Update on Invivyd Analysts have reaffirmed a $10 price target for Invivyd, citing the view that the recent post earnings selloff tied to a Q1 revenue miss and higher research and development spend was overdone. Upcoming VYD2311 data and a potential biologics license application are seen as the main drivers for maintaining this valuation level.Narrative-Update • Apr 26
IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. They are keeping fair value around $10.00 per share while fine tuning the risk and profitability profile that underpins the estimate.Narrative-Update • Apr 11
IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to $10.00 from $10.00, reflecting updated views on discount rate, revenue growth expectations, profit margin and future P/E assumptions. What's in the News Invivyd reported progress in the REVOLUTION clinical program for VYD2311, including the pivotal DECLARATION Phase 3 study assessing VYD2311 for pre-exposure COVID-19 prophylaxis versus placebo over 90 days, with a blinded sample size re-estimation that triggered an upsizing of approximately 500 subjects to support statistical power.Narrative-Update • Mar 26
IVVD: Phase 3 COVID Prevention And Long COVID Trial Will Drive Upside
Narrative Update on Invivyd Analysts have modestly adjusted their price view on Invivyd, with the updated fair value holding at $10.00. Small tweaks to discount rate, revenue growth, profit margin assumptions, and a higher future P/E estimate of about 282x refine the underlying model rather than signal a major shift in conviction.Seeking Alpha • Mar 20
Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching
Summary Invivyd, Inc. is advancing VYD2311, a next-gen monoclonal antibody for COVID-19 prevention, with pivotal Phase 3 DECLARATION data expected mid-2026. IVVD's Pemgarda generated $53.4M in 2025 revenue, but fell short of management expectations; net loss narrowed to $(52.5M) from $(170M) prior year. IVVD secured FDA Fast Track for VYD2311 and raised ~$200M in 2H 2025, providing at least two years of funding at current burn rates. I view IVVD stock as a high-risk, high-reward opportunity; DECLARATION study success could drive shares up 75%, but failure could see stock revisit sub-$0.5 levels. Read the full article on Seeking AlphaNarrative-Update • Mar 10
IVVD: Fast Track Phase 3 COVID Prevention Program Will Drive Future Upside
Analysts have adjusted their price target on Invivyd to reflect updated assumptions around revenue growth of 71.06%, a profit margin of 5.97% and a future P/E of 266.11x. These assumptions result in a revised fair value estimate of $10.00 per share.Narrative-Update • Feb 23
IVVD: Phase 3 Fast Track COVID Prevention Trials Will Support Future Upside
Analysts have kept their fair value estimate for Invivyd steady at $10.00. A slightly lower discount rate and modestly softer profit margin outlook, paired with a marginally higher future P/E assumption, reflect a more finely balanced view of the company’s risk and earnings potential.Narrative-Update • Feb 09
IVVD: Phase 3 Fast Track COVID Prevention Program Will Drive Future Upside
Analysts have trimmed their price target on Invivyd to US$10, citing updated assumptions that include a slightly higher discount rate, modestly reduced profit margin expectations, and a higher future P/E multiple. What's in the News FDA granted Fast Track designation for VYD2311, Invivyd's vaccine alternative monoclonal antibody candidate for prevention of COVID in individuals with underlying risk factors for severe disease, aligning the program with an expedited U.S. regulatory process (Key Developments).Analyseartikel • Jan 29
Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk
The Invivyd, Inc. ( NASDAQ:IVVD ) share price has softened a substantial 26% over the previous 30 days, handing back...Narrative-Update • Jan 24
IVVD: REVOLUTION Program Will Define Future Upside As COVID Prevention Alternative
Analysts have lifted their price target on Invivyd to US$10 from US$5, citing the launch of the REVOLUTION clinical program for VYD2311 as a key driver behind their updated view. Analyst Commentary Analysts are reacting to the REVOLUTION program for VYD2311 as a key event for Invivyd, and the updated US$10 price target reflects how they are recalibrating risk and potential upside around this new clinical path.Narrative-Update • Jan 08
IVVD: REVOLUTION Program And Fast Track Status Will Support Future Upside Potential
Narrative Update on Invivyd Analysts have lifted their price target on Invivyd to US$10 from US$5, pointing to the launch of the REVOLUTION clinical program for VYD2311 as a key factor that they believe strengthens the company’s regulatory and commercial position. Analyst Commentary Recent Street research around Invivyd has focused squarely on the launch of the REVOLUTION clinical program for VYD2311, with bullish analysts recalibrating their expectations for the company’s potential market position and execution risk.Narrative-Update • Dec 18
IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside
Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION clinical program for VYD2311 as a meaningful inflection point that enhances the company’s regulatory and commercial outlook. Analyst Commentary Following the launch of the REVOLUTION clinical program for VYD2311, equity research has focused on how the new data and development path could reshape Invivyd's long term growth and valuation profile.Narrative-Update • Dec 04
IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside
Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION program for VYD2311 as a key inflection point that improves the company's regulatory and commercial outlook. Analyst Commentary Analysts interpreting the updated price target see the REVOLUTION program as a pivotal moment for Invivyd, shifting expectations for both execution and long term growth potential.Analyseartikel • Nov 29
Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking
Despite an already strong run, Invivyd, Inc. ( NASDAQ:IVVD ) shares have been powering on, with a gain of 27% in the...Narrative-Update • Nov 20
IVVD: REVOLUTION Program Initiation Will Drive Regulatory Momentum and Commercial Outlook
Analysts have raised their price target for Invivyd from $5 to $10, citing the launch of the REVOLUTION clinical program as a pivotal development. This new program is expected to enhance the company's regulatory and commercial outlook.Narrative-Update • Nov 05
IVVD: FDA Clearance and REVOLUTION Program Launch Signal Strong Upside Ahead
Narrative Update: Invivyd Analyst Price Target Increased Invivyd's analyst price target has been raised from $5.67 to $7.33 per share. Analysts cite strengthened commercial and regulatory prospects following the launch of the REVOLUTION clinical program.Narrative-Update • Oct 22
Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update
Narrative Update on Invivyd: Analyst Price Target Revision Analysts have maintained Invivyd's price target at $5.67, citing consistent profit margin expectations along with only minor adjustments to the discount rate and future earnings estimates. What's in the News The FDA has cleared Invivyd's Investigational New Drug application, advancing the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Product-Related Announcements).Analyseartikel • Oct 14
Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Invivyd, Inc. ( NASDAQ:IVVD ) shares have continued their recent momentum with a 31% gain in the last month alone. The...Narrative-Update • Oct 08
Internal Sales And Antibody Pipeline Will Broaden Patient Reach
Narrative Update on Invivyd Price Target Analysts have raised Invivyd’s price target from $3.00 to $5.67, citing updated forecasts and changes in market expectations. What's in the News The U.S. FDA cleared Invivyd’s Investigational New Drug application, enabling advancement of the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Key Developments).Analyseartikel • Aug 22
Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge
Invivyd, Inc. ( NASDAQ:IVVD ) shareholders that were waiting for something to happen have been dealt a blow with a 31...Narrative-Update • Aug 16
Internal Sales And Antibody Pipeline Will Broaden Patient Reach
Invivyd’s fair value estimate has been sharply reduced, driven by lowered revenue growth projections and a decline in expected net profit margins, resulting in a consensus analyst price target drop from $4.93 to $2.93. What's in the News Invivyd’s monoclonal antibody pemivibart (PEMGARDA) has shown strong protection (84% relative risk reduction) against symptomatic COVID-19 in immunocompromised and at-risk populations in the placebo-controlled CANOPY Phase 3 trial, supporting its Emergency Use Authorization (EUA) for pre-exposure prophylaxis.
Neues Narrative • Apr 23
Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025
The development of next-generation antibodies could expand market reach and improve margins by lowering production and administration costs.Seeking Alpha • Feb 04
I See The Bull Case For Invivyd, But I'm Not Married To It
Summary Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% revenue increase for PEMGARDA and a 55% drop in operating expenses highlights Invivyd's potential for profitability. VYD2311 shows significant promise with high neutralization potency and durability, but faces regulatory and competitive challenges before market approval. Invivyd is a speculative bet with potential for high rewards; suitable for risk-tolerant investors, but stability seekers should avoid. Read the full article on Seeking AlphaAnalyseartikel • Feb 01
Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analyseartikel • Jul 16
Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Geschäftsführer
Marc Elia (50 yo)
less than a year
Amtszeit
US$125,960
Vergütung
Mr. Marc William Elia is CEO & Chairperson of the Board of Invivyd, Inc. from August 30, 2026. Mr. Elia was Independent Chairperson of the Board of Invivyd, Inc. from July 2022 to August 30, 2026. Mr. Elia...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Chairperson of the Board | less than a year | US$125.96k | keine Daten | |
| CFO and Principal Financial & Accounting Officer | 3yrs | US$2.14m | 0.057% $ 132.7k | |
| Chief Legal Officer & Corporate Secretary | 4.8yrs | US$2.49m | 0.096% $ 223.3k | |
| Chief Commercial Officer | 2.3yrs | US$2.10m | 0.061% $ 140.6k | |
| Chief Scientific Officer | 3.4yrs | US$2.16m | 0.061% $ 140.4k | |
| Chief Communications Officer | 1yr | keine Daten | keine Daten | |
| Chief Human Resources Officer | 3.7yrs | US$1.59m | 0.057% $ 132.7k | |
| Senior Vice President of Regulatory Affairs | less than a year | keine Daten | keine Daten | |
| Senior Vice President of Finance | no data | keine Daten | keine Daten | |
| Chief Medical Officer & Chief Epidemiologist | less than a year | keine Daten | keine Daten |
2.3yrs
Durchschnittliche Betriebszugehörigkeit
52yo
Durchschnittliches Alter
Erfahrenes Management: IVVDDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Chairperson of the Board | 4.3yrs | US$125.96k | keine Daten | |
| Independent Director | 5.9yrs | US$84.46k | keine Daten | |
| Independent Director | 2.3yrs | US$101.61k | 0.017% $ 39.3k | |
| Independent Director | less than a year | keine Daten | keine Daten | |
| Lead Independent Director | 1.5yrs | US$110.16k | keine Daten | |
| Independent Director | 1yr | US$134.35k | keine Daten | |
| Independent Director | 4.3yrs | US$87.96k | 0% $ 0 |
2.3yrs
Durchschnittliche Betriebszugehörigkeit
50yo
Durchschnittliches Alter
Erfahrener Vorstand: IVVDDie Vorstandsmitglieder gelten nicht als erfahren ( 2.3 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/13 01:30 |
| Aktienkurs zum Tagesende | 2026/09/11 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Invivyd, Inc. wird von 5 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Thomas Shrader | BTIG |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Patrick Trucchio | H.C. Wainwright & Co. |